ClinicalTrials.gg
CompletedNCT01907113Updated Jul 14, 2014Results posted

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

A Phase 1 interventional study of BI 10773 and BI 10773 in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 2 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
90th of 130
40 · median 79
Started
2009
with 3 others
Phase 1
24 of 130
5 open now
Registered
29th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 90th largest by enrollment, is one of 4 that started in 2009, is one of 24 in phase 1, and was the 29th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects with type 2 diabetes
  2. Renally impaired male or female subjects
  3. Age 18 - 75 years
  4. 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index)
  5. Signed and dated written

Exclusion criteria

Exclusion criteria:

  1. Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator.
  2. Relevant gastrointestinal tract surgery
  3. Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders
  4. History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure \< 100 or > 160 mm Hg, diastolic blood pressure \< 60 or > 100 mm Hg, pulse rate \< 50 or > 100 1/min
  5. Chronic or relevant acute infections
  6. History of allergy/ (including drug allergies) that are deemed relevant to the trial as judged by the investigator
  7. Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.

    • protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir)
    • azole antimycotics, (itraconazole, ketoconazole, miconazole)
    • macrolid antibiotics, (clarithromycin, erythromycin)
    • amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St. John's wort, troglitazone. In dubious cases, a case by case decision will be made after consultation with the sponsor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    BI 10773 / Group 2

    Single Dose Administration (type 2 diabetes and mild renal impairment)

    Drug: BI 10773

  • Experimental
    BI 10773 / Group 3

    Single Dose Administration (type 2 diabetes and moderate renal impairment)

    Drug: BI 10773

  • Experimental
    BI 10773 / Group 4

    Single Dose Administration (severe renal impairment 8)

    Drug: BI 10773

  • Experimental
    BI 10773 / Group 5

    Single Dose Administration (kidney failure)

    Drug: BI 10773

  • Experimental
    BI 10773 / Group 1

    Single Dose Administration (type 2 diabetes and normal renal function)

    Drug: BI 10773

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)

    Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.

    Time frame: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  2. Cmax (Maximum Concentration of the Analyte in Plasma)

    Maximum concentration of Empagliflozin in plasma

    Time frame: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

Secondary outcomes

  1. Time to Maximum Concentration of the Analyte in Plasma

    Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  2. Half-life and Mean Residence Time of the Analyte in Plasma

    Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  3. Terminal Rate Constant in Plasma

    Terminal rate constant in plasma (Lz)

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  4. Apparent Clearance of the Analyte in the Plasma After Extravascular Administration

    Apparent clearance of the analyte in the plasma after extravascular administration

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  5. Apparent Volume of Distribution During the Terminal Phase Lz

    Apparent volume of distribution during the terminal phase Lz

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  6. AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  7. Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)

    Amount of analyte that is eliminated in urine over the time interval 0-96 hours.

    Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration

  8. fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)

    Fraction of analyte excreted unchanged in urine from time point 0-96 hours.

    Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration

  9. Renal Clearance of the Analyte in Plasma After Extravascular Administration

    Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.

    Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration

  10. %AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)

    Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity

    Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration

  11. Plasma Protein Binding

    Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.

    Time frame: 1 h before drug administration and 1:30 and 3:00 h after drug administration

  12. Total Urinary Glucose Excretion (UGE)

    Change from baseline in total urinary glucose excretion

    Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)

  13. Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements

    Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements

    Time frame: Drug administration until end-of-study-examination, 5 days

  14. Assessment of Tolerability by Investigator

    Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.

    Time frame: Drug administration until end-of-study-examination, 5 days

07

Results

Posted Jul 14, 2014

Participant flow

The trial was conducted in two trial centres as an open-label, parallel group design with one treatment period. The trial was performed in 40 male and female patients who were assigned to five treatment groups according to their creatinine clearance.

Participant flow — Overall Study
MilestoneNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Started89788
Completed89788
Not completed00000

Outcome measures

PrimaryAUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)

Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.

Time frame:
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
nmol*h/LNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)10500 ± 17.612400 ± 21.612600 ± 27.117500 ± 18.915600 ± 38.6
Statistical analysis
  • Normal Renal Function vs Mild Renal Impairment · ANOVA · Geometric mean ratio: 118.24 · 90% CI 96.17 to 145.38Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Geometric mean ratio: 119.94 · 90% CI 96.25 to 149.47Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Geometric mean ratio: 166.29 · 90% CI 134.44 to 205.68Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Kidney Failure · ANOVA · Geometric mean ratio: 148.29 · 90% CI 119.89 to 183.42Standard deviation is actually the geometric Coefficient of Variation \[%\].
PrimaryCmax (Maximum Concentration of the Analyte in Plasma)

Maximum concentration of Empagliflozin in plasma

Time frame:
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · nmol/L
Cmax (Maximum Concentration of the Analyte in Plasma)
nmol/LNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Cmax (Maximum Concentration of the Analyte in Plasma)1210 ± 24.11430 ± 33.11230 ± 30.91450 ± 33.01250 ± 25.9
Statistical analysis
  • Normal Renal Function vs Mild Renal Impairment · ANOVA · Geometric mean ratio: 118.83 · 90% CI 93.62 to 150.84Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Geometric mean ratio: 102.27 · 90% CI 79.33 to 131.85Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Geometric mean ratio: 120.68 · 90% CI 94.42 to 154.25Standard deviation is actually the geometric Coefficient of Variation \[%\].
  • Normal Renal Function vs Kidney Failure · ANOVA · Geometric mean ratio: 103.75 · 95% CI 81.18 to 132.61Standard deviation is actually the geometric Coefficient of Variation \[%\].
SecondaryTime to Maximum Concentration of the Analyte in Plasma

Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Median · h
Time to Maximum Concentration of the Analyte in Plasma
hNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Time to Maximum Concentration of the Analyte in Plasma1.00 (1.00 to 3.00)2.50 (2.00 to 4.00)2.00 (1.50 to 3.00)2.00 (0.67 to 4.00)2.50 (1.50 to 3.00)
SecondaryHalf-life and Mean Residence Time of the Analyte in Plasma

Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · h
Half-life and Mean Residence Time of the Analyte in Plasma
hNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Terminal half-life17.4 ± 57.419.3 ± 81.619.5 ± 63.922.5 ± 74.318.5 ± 62.6
Mean residence time13.1 ± 37.415.7 ± 44.618.4 ± 52.722.2 ± 57.619.8 ± 51.2
SecondaryTerminal Rate Constant in Plasma

Terminal rate constant in plasma (Lz)

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · 1/h
Terminal Rate Constant in Plasma
1/hNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Terminal Rate Constant in Plasma0.0398 ± 57.40.0360 ± 81.60.0355 ± 63.90.0308 ± 74.30.0375 ± 62.6
SecondaryApparent Clearance of the Analyte in the Plasma After Extravascular Administration

Apparent clearance of the analyte in the plasma after extravascular administration

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · mL/min
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
mL/minNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration176 ± 17.6149 ± 21.6147 ± 27.1106 ± 18.9119 ± 38.6
SecondaryApparent Volume of Distribution During the Terminal Phase Lz

Apparent volume of distribution during the terminal phase Lz

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Phase Lz
LNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Apparent Volume of Distribution During the Terminal Phase Lz266 ± 55.1248 ± 76.3248 ± 55.5206 ± 78.0190 ± 45.1
SecondaryAUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
nmol*h/LNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)10300 ± 17.512100 ± 20.912100 ± 24.416500 ± 19.914900 ± 34.4
SecondaryAe0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)

Amount of analyte that is eliminated in urine over the time interval 0-96 hours.

Time frame:
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Reported as:
Geometric mean · nmol
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
nmolNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)17300 ± 26.112100 ± 43.86840 ± 85.53730 ± 49.3300 ± 117
Secondaryfe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)

Fraction of analyte excreted unchanged in urine from time point 0-96 hours.

Time frame:
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Reported as:
Geometric mean · percentage of analyte
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
percentage of analyteNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)15.6 ± 26.110.9 ± 43.86.16 ± 85.53.36 ± 49.30.271 ± 117
SecondaryRenal Clearance of the Analyte in Plasma After Extravascular Administration

Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.

Time frame:
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Reported as:
Geometric mean · mL/min
Renal Clearance of the Analyte in Plasma After Extravascular Administration
mL/minNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Renal Clearance of the Analyte in Plasma After Extravascular Administration28.0 ± 19.516.7 ± 53.79.39 ± 87.93.70 ± 38.50.349 ± 188
Secondary%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)

Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity

Time frame:
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Reported as:
Geometric mean · percent
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
percentNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)0.869 ± 2251.07 ± 2431.21 ± 2231.78 ± 3341.14 ± 330
SecondaryPlasma Protein Binding

Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.

Time frame:
1 h before drug administration and 1:30 and 3:00 h after drug administration
Reported as:
Mean · percentage of plasma protein binding
Plasma Protein Binding
percentage of plasma protein bindingNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Pre-dose83.61 ± 1.1082.72 ± 3.3681.29 ± 2.4879.98 ± 2.4281.08 ± 1.54
1:30 h after dosing85.18 ± 1.9183.70 ± 2.4982.68 ± 2.7681.02 ± 1.7381.09 ± 1.94
3:00 h after dosing83.94 ± 1.8883.18 ± 2.5881.90 ± 1.6980.38 ± 1.6180.32 ± 2.00
SecondaryTotal Urinary Glucose Excretion (UGE)

Change from baseline in total urinary glucose excretion

Time frame:
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
Reported as:
Mean · mg
Total Urinary Glucose Excretion (UGE)
mgNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Total Urinary Glucose Excretion (UGE)97643 ± 720461590 ± 689255674 ± 1689118251 ± 3925779 ± 904
SecondarySafety: Physical Examination, Vital Signs, ECG and Laboratory Measurements

Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements

Time frame:
Drug administration until end-of-study-examination, 5 days
Reported as:
Number · participants
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
participantsNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Physical examination00000
Vital signs00000
ECG00000
Laboratory Measurements00000
SecondaryAssessment of Tolerability by Investigator

Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.

Time frame:
Drug administration until end-of-study-examination, 5 days
Reported as:
Number · participants
Assessment of Tolerability by Investigator
participantsNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
Good89788
Satisfactory00000
Not satisfactory00000
Bad00000
Not assessable00000

Adverse events

Collected over From drug administration until end of trial examination, 5 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Renal Function—0/8 (0%)1/8 (12.5%)
Mild Renal Impairment—0/9 (0%)0/9 (0%)
Moderate Renal Impairment—0/7 (0%)1/7 (14.3%)
Severe Renal Impairment—0/8 (0%)0/8 (0%)
Kidney Failure—0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventNormal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney Failure
ErythemaMetabolism and nutrition disorders0/80/91/70/80/8
PruritusSkin and subcutaneous tissue disorders0/80/91/70/81/8
DiarrhoeaGastrointestinal disorders0/80/90/70/81/8
NauseaGastrointestinal disorders1/80/90/70/80/8
HeadacheNervous system disorders1/80/90/70/80/8

Baseline characteristics

The treated set included all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(years)Normal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney FailureTotal
Mean54.5 ± 11.760.0 ± 8.863.1 ± 9.556.0 ± 12.945.8 ± 12.055.8 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Normal Renal FunctionMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentKidney FailureTotal
Female7631421
Male1347419
08

Study locations

2 sites
  • 1245.12.1 Boehringer Ingelheim Investigational Site
    Kiel, Germany
  • 1245.12.2 Boehringer Ingelheim Investigational Site
    Neuss, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2013
First posted
Jul 24, 2013
Start
Jul 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Jul 14, 2014
Last update
Jul 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01907113
Responsible party
Sponsor
First posted
Jul 24, 2013
Start date
Jul 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Jul 14, 2014
Last update
Jul 14, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion